AbClon KRX:174900KOSDAQ
앱클론 · Korean news coverage and regulatory filings, organized.
In Q3 2026, AbClon reported revenue of ₩1.8bn, up 12.9% year on year, and an operating loss of ₩3.9bn. AbClon (앱클론) appeared in 23 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 9 with 17 articles. The most common catalyst was tech & capacity (15). It was most often mentioned alongside Chong Kun Dang Pharmaceutical, 글로벌테크놀로지 and Kangstem Biotech.
Filing signals Supply contract Clinical trial filing 4 quarters of losses Screener
AbClon today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates AbClon stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
AbClon quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩1.8bn | +12.9% | −₩3.9bn margin −219.8% | −₩3.8bn |
| Q2 2026 | ₩1.7bn | +51.4% | −₩6.3bn | −₩6.1bn |
| Q1 2026 | ₩434m | +5.2% | −₩3.1bn | −₩2.8bn |
| Q4 2025 derived | ₩1.6bn | +128.6% | −₩5.0bn | −₩5.1bn |
| Q3 2025 | ₩1.6bn | +96.3% | −₩3.5bn margin −225.9% | −₩3.5bn |
| Q2 2025 | ₩1.1bn | +181.8% | −₩3.3bn | −₩3.5bn |
| Q1 2025 | ₩413m | -5.6% | −₩5.8bn | −₩6.0bn |
| Q4 2024 derived | ₩710m | +26.0% | −₩3.2bn | −₩3.3bn |
AbClon ranks #2156 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
AbClon top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest AbClon news Korean headlines
-
MajorAppClone's CAR-T 'Nespercell' receives European patent…secures rights in eight major markets
5 more on this story · 5 outlets
- AppClone's CAR-T 'Nespercell' receives European patent…secures rights in eight major markets한국경제 · Nov 11 09:05
- Apclone's Nesphacel gains European patent, secures rights in major markets through 2038서울경제 · Nov 11 09:20
- Appclone rises 12.93% on Nesphecel European patent registration, secures rights in eight global markets남도일보 · Nov 11 09:26
- Appclone secures Nesphercell European patent registration, establishes rights in eight global markets이뉴스투데이 · Nov 11 14:04
- Appclone completes European patent registration for CAR-T 'Nespeucel'메디파나뉴스 · Nov 11 15:25
-
AppClone's next-gen CAR-T 'Nesphecel' granted final European patent...secures monopoly rights in eight global markets
5 more on this story · 5 outlets
- AppClone's CAR-T therapy 'Nespercell' receives European patent…secures rights in eight global markets이투데이 · Nov 11 09:07
- Apclone secures European patent for Nesphacel, exclusive rights in 8 major global markets머니투데이 · Nov 11 09:16
- Appclone secures European patent for Nesphecel, acquires rights in eight major marketsPRESS9 · Nov 11 09:24
- Appclone registers Nespicell European patent... secures IP in eight major global marketsEBN · Nov 11 11:03
- AppClone, Nespresso Europe patent registered...secures rights in 8 major global markets뉴스1 · Nov 11 15:04
-
AppClone secures exclusive Korean sales rights for Celltrion's next-generation CAR-T 'Nesspercell'
1 more on this story · 1 outlets
-
MajorAppclone, Chong Kun Dang sign exclusive domestic sales contract for CAR-T therapy Nesphacel
12 more on this story · 12 outlets
- Appclone signs final contract with Chong Kun Dang for exclusive domestic sales of 'Nesphaseal'메디포뉴스 · Nov 9 13:16
- Appclone, Chong Kun Dang finalize contract for next-generation CAR-T 'Nesphaseal' domestic supply and sales머니투데이 · Nov 9 13:32
- Appclone, Chong Kun Dang sign exclusive domestic sales contract for CAR-T Nespecel메디파나뉴스 · Nov 9 13:40
- AppClone signs definitive agreement with Chong Kun Dang on CAR-T 'Nesphecel' domestic exclusive sales히트뉴스 · Nov 9 14:04
- AppClone and Chong Kun Dang sign supply and sales contract for CAR-T therapeutic Nesphacel domestically조선비즈 · Nov 9 14:13
- AppClone and Chong Kun Dang conclude CAR-T domestic exclusive sales contract뉴시스경제 · Nov 9 14:19
- AppClone and Chong Kun Dang sign supply and sales contract for CAR-T therapeutic Nesphacel domestically조선일보 · Nov 9 14:20
- AppClone signs exclusive domestic sales agreement with Chong Kun Dang for CAR-T therapy Nespercell뉴스1 · Nov 9 14:52
- Indigenous CAR-T commercialization within reach, Apclone and Chong Kun Dang sign domestic exclusive license agreement for Nespcel와이드경제 · Nov 9 15:40
- AppClone signs exclusive domestic sales contract with Chong Kun Dang for CAR-T therapeutic 'Nesphacel'서울경제 · Nov 9 16:47
- AppClone signs exclusive domestic sales contract with Chong Kun Dang for CAR-T therapeutic 'Nesphacel'이뉴스투데이 · Nov 9 17:40
- AppClone signs definitive agreement with Chong Kun Dang for CAR-T therapeutic 'Nespercell' domestic supply and sales팍스경제TV · Nov 10 00:03